From APL on ymb
I think today is a good day to post this again. Day 63. Still no 13D plan. This could be why:
Interesting info from another board. There is a pattern here. Prostagene acquired because it had a great test kit. Which turned out to be not true. Now, 13D's are enamored with IncellDx, because Dr. P. has a great test kit. Carraciola, a former Gilead VP, is one of the common threads here. Follow the dots. 2012 cytodyn buys pro140, Nader is ceo at that time. 2013 Tony C is named chairman of board.
Jan 2017 Tony named executive chairman, effectively replacing Nader. Google "what does an executive Chairman of the Board do?" Nader is still ceo but Tony is in charge of planning, business dev. And operations.
Aug 2018 cytodyn agrees to buy Prostagene. Pestell becomes CMO. Strategic Initiatives like acquisitions are one of responsibilities of an executive chairman. Tony C. resigns his role as executive chairman after the agreement to acquire Prostagene is made and becomes just the chairman. Pestell joins the BoD Nov 2018. July 2019, Pestell is fired for cause. In August Pestell sues cytodyn.
In Aug 2019 cytodyn has meeting with fda to discuss Prostagene's test kit. Following the meeting, it becomes clear the investment to secure 510(K) approval would be substantial. The test kit that was "ready for market" just isn't.
Dec 2018, Tony C. was replaced by Scott Kelly as cob.
April 2020 the original BLA for combo was filed
May of 2020 is when the fda had some problem with it
July 2020 is when we got the RTF. Dr. P. dropped shortly after that. All these people are key players in the 13d group. Any chance of replacing the Nader mgmnt team and bod is counting on the ignorance of retail investors to this info. Based on the past it seems Tony, Pestell and Bruce are all in it for personal enrichment. The first thing the 13d group wants to do is buy IncellDx, at SH expense, enriching Bruce and his investors. Just like what Tony did for Pestell. Nader has tried to navigate these expensive distractions by focusing on getting leronlimab through trials, raising money to pay for it and getting distribution deals. This is as plain as I can make it, don’t listen to this group's attempt to make everything a Nader problem, it is their doing from all the way back in 2017 when Tony, an ex gilead VP, became Executive CoB.
Based on this history, it doesn't appear to be a coincidence that the ECOR approval secured by Drs. Errico and Staats was a 510(K) approval. So the apparent plan is to have SH's pay for acquiring IncellDx through a dilutive offering, enriching themselves and then spending even more money pushing to secure a 510(K) approval for IncellDx test kits, which could take years, while putting leronlimab on the back burner or selling it out for pennies on the dollar, which helps.... wait for it.... Big Pharma. And this time, the cost for the acquisition won't be $15.4M. It will probably be closer to $150M. And now that I think about it, what is to prevent them from making a play to merge ECOR into CYDY? And they could do this prior to selecting new executive officers by appointing Mr. Rosenbaum as Executive Chairman. With Drs. Patterson, Errico, and Staats sitting on the board, this would be the ultimate in self dealing. Do your DD. Follow the dots. Don't trust what you don't know. The 13D's have shared nothing pertinent with you. Retail investors have tools
available today that never existed before. Which allowed folks like 13D's to bamboozle uninformed investors in the past. That isn't the case today. As a whole, retail investors the days are much better informed and know where to go in order to triage the truth. We are in the driver's seat. There are alot of back seat drivers telling you that you don't know where you're going and are lost. I know exactly where I'm going, and who has my best interests at heart. #TeamCYDY
